These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 32409420)

  • 1. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.
    Huang T; Ren X; Tang X; Wang Y; Ji R; Guo Q; Ma Q; Zheng Y; Hu Z; Zhou Y
    Front Immunol; 2024; 15():1427380. PubMed ID: 39188712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease.
    Shuai C; Xia GQ; Yuan F; Wang S; Lv XW
    Eur J Pharmacol; 2021 Aug; 905():174198. PubMed ID: 34033815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD39/CD73/A2a Adenosine Metabolic Pathway: Targets for Moxibustion in Treating DSS-Induced Ulcerative Colitis.
    Zhu Y; Zhuang Z; Wu Q; Lin S; Zhao N; Zhang Q; Xie L; Yu S
    Am J Chin Med; 2021; 49(3):661-676. PubMed ID: 33683190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
    Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
    Bönner F; Borg N; Burghoff S; Schrader J
    PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
    Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
    J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the CD39-CD73-adenosine pathway in liver disease.
    Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
    J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical and functional analysis of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) and ecto-5'-nucleotidase (CD73) in pig aortic valves.
    Kaniewska E; Sielicka A; Sarathchandra P; Pelikant-Małecka I; Olkowicz M; Słomińska EM; Chester AH; Yacoub MH; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):305-12. PubMed ID: 24940684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
    Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
    PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
    Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
    Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation.
    Sattler C; Steinsdoerfer M; Offers M; Fischer E; Schierl R; Heseler K; Däubener W; Seissler J
    Cell Transplant; 2011; 20(8):1221-30. PubMed ID: 21176405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
    Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
    FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.